A Personalized Approach to Treatment While standard semaglutide protocols show meaningful results for many patients, a personalized approach may help optimize outcomes beyond one-size-fits-all dosing
This shift not only benefits patients but also expands the market potential for pharmaceutical companies
Conclusion As a starting point to inform deeper investigations into real-world variation and patient profiles for responsiveness to therapies, our research bridges the gap between clinical trials and GLP-1 use in the real world, where a broader, more diverse population is using GLP-1s in a variety of settings and personal contexts
Clinical trial results for retatrutide have exceeded even the high expectations set by tirzepatide, with Phase 2 data published in the New England Journal of Medicine in 2023 demonstrating weight loss approaching 24-25% of baseline body weight over 48 weeks in some dose groups - weight reductions comparable to those achieved with bariatric surgery and substantially exceeding pharmacological obesity treatments available just a few years ago
While more research is needed, preliminary studies suggest this combination approach may address multiple factors contributing to midlife weight changes
During the dose escalation period, focus on a protein-rich diet with complex carbohydrates and healthy fats